S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
NYSE:NVS

Novartis - NVS Stock Forecast, Price & News

$89.49
-0.35 (-0.39%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$89.27
$89.99
50-Day Range
$86.79
$92.81
52-Week Range
$74.09
$94.26
Volume
1.70 million shs
Average Volume
1.98 million shs
Market Capitalization
$198.01 billion
P/E Ratio
9.20
Dividend Yield
2.42%
Price Target
$85.11

Novartis MarketRank™ Forecast

Analyst Rating
Hold
1.92 Rating Score
Upside/​Downside
4.9% Downside
$85.11 Price Target
Short Interest
Healthy
0.24% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.15mentions of Novartis in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.63%
From $6.03 to $6.49 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

718th out of 1,054 stocks

Pharmaceutical Preparations Industry

362nd out of 517 stocks


NVS stock logo

About Novartis (NYSE:NVS) Stock

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

Pliant Therapeutics Gaps 34% Higher: More Upside To Come? (NVS)
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Citigroup Lowers Novartis (NYSE:NVS) to Neutral
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Top Stock Reports for NIKE, Novartis & Wells Fargo
Check Out What Whales Are Doing With NVS
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Novartis' (NVS) PNH Candidate Achieves Study Objectives
Novartis: Phase III PSMAfore Study With Pluvicto Meets Primary Endpoint
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
Novartis shifting all gene therapy production to Durham
Novartis AG (NVS) Q3 2022 Earnings Call Transcript
Novartis Whale Trades For October 24
Recap: Novartis Q3 Earnings
Novartis: Healthy Results
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
Novartis (NVS) Q3 2022 Earnings Call Transcript
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Company Calendar

Last Earnings
10/25/2021
Today
1/29/2023
Next Earnings (Confirmed)
2/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
104,323
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$85.11
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
-4.9%
Consensus Rating
Hold
Rating Score (0-4)
1.92
Research Coverage
12 Analysts

Profitability

Net Income
$24.02 billion
Pretax Margin
46.16%

Debt

Sales & Book Value

Annual Sales
$51.63 billion
Cash Flow
$9.02 per share
Book Value
$30.32 per share

Miscellaneous

Outstanding Shares
2,212,600,000
Free Float
2,212,379,000
Market Cap
$198.01 billion
Optionable
Optionable
Beta
0.55

Social Links


Key Executives

  • Vasant Narasimhan
    Chief Executive Officer
  • Steffen Lang
    President-Operations
  • Harry Werner Kirsch
    Chief Financial Officer
  • Shreeram Aradhye
    Chief Medical Officer
  • Klaus Moosmayer
    Chief Ethics, Risk & Compliance Officer













NVS Stock - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 3 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price forecast for 2023?

12 analysts have issued twelve-month target prices for Novartis' stock. Their NVS share price forecasts range from $70.00 to $105.00. On average, they expect the company's share price to reach $85.11 in the next twelve months. This suggests that the stock has a possible downside of 4.9%.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2023?

Novartis' stock was trading at $90.72 at the beginning of 2023. Since then, NVS stock has decreased by 1.4% and is now trading at $89.49.
View the best growth stocks for 2023 here
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023.
View our NVS earnings forecast
.

How can I listen to Novartis' earnings call?

Novartis will be holding an earnings conference call on Wednesday, February 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings results on Monday, October, 25th. The company reported $1.71 earnings per share for the quarter, beating analysts' consensus estimates of $1.65 by $0.06. The firm had revenue of $13.03 billion for the quarter, compared to the consensus estimate of $13.02 billion. Novartis had a net margin of 42.66% and a trailing twelve-month return on equity of 20.89%. The firm's revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.52 earnings per share.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Thursday, February 3rd. Stockholders of record on Wednesday, March 9th will be given a dividend of $1.175 per share on Thursday, March 17th. This represents a yield of 1.36%. The ex-dividend date of this dividend is Tuesday, March 8th.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.16 per share and currently has a dividend yield of 2.41%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 22.20%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 33.28% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by many different retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.08%), Natixis Advisors L.P. (0.06%), Bristol John W & Co. Inc. NY (0.03%), MUFG Securities EMEA plc (0.03%), Cambridge Trust Co. (0.01%) and Boston Common Asset Management LLC (0.01%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $89.49.

How much money does Novartis make?

Novartis (NYSE:NVS) has a market capitalization of $198.01 billion and generates $51.63 billion in revenue each year. The company earns $24.02 billion in net income (profit) each year or $9.73 on an earnings per share basis.

How many employees does Novartis have?

The company employs 104,323 workers across the globe.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The official website for the company is www.novartis.com. The company can be reached via phone at (161) 324-1111, via email at investor.relations@novartis.com, or via fax at 41-61-324-7826.

This page (NYSE:NVS) was last updated on 1/29/2023 by MarketBeat.com Staff